SeekingAlpha · Oct 28, 2026
AM
NASDAQ · AMRN
Amarin Corporation plc
Healthcare · Biotechnology
$12.11
Down-$0.63 (-4.91%)
Updated Nov 2, 2026, 9:08 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 285.42M
- P/E ratio
- -147.97
- Dividend yield
- 0.00%
- 52-week range
- $11.25 – $17.25
- Volume
- 101.28K
- Avg. volume
- 93.27K
Price performance · AMRN
AMRN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
AMRN closed at $12.11 after 20 trading sessions, up 0.17% for the selected period.
- Last close
- $12.11
- Period change
- +0.17%
- Period low
- $11.32
- Period high
- $12.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $12.71 | $12.76 | $12.00 | $12.11 | 101.28K |
| Oct 29, 2026 | $12.79 | $13.18 | $12.68 | $12.735 | 40.04K |
| Oct 28, 2026 | $12.20 | $13.01 | $12.10 | $12.745 | 161.3K |
| Oct 27, 2026 | $12.06 | $12.1899 | $11.95 | $11.95 | 56.89K |
| Oct 26, 2026 | $12.04 | $12.17 | $11.70 | $12.09 | 64.82K |
| Oct 23, 2026 | $11.51 | $11.965 | $11.401 | $11.79 | 83.27K |
| Oct 22, 2026 | $11.40 | $11.65 | $11.25 | $11.60 | 27.36K |
| Oct 21, 2026 | $11.60 | $11.67 | $11.46 | $11.51 | 37.95K |
| Oct 20, 2026 | $11.50 | $11.86 | $11.48 | $11.48 | 29.14K |
| Oct 19, 2026 | $11.41 | $11.59 | $11.32 | $11.53 | 78.06K |
| Oct 16, 2026 | $11.5001 | $11.625 | $11.25 | $11.32 | 113.66K |
| Oct 15, 2026 | $11.57 | $11.845 | $11.5592 | $11.57 | 54.36K |
| Oct 14, 2026 | $11.47 | $11.785 | $11.4001 | $11.61 | 51.01K |
| Oct 13, 2026 | $11.53 | $11.62 | $11.34 | $11.58 | 102.39K |
| Oct 12, 2026 | $11.93 | $11.93 | $11.39 | $11.53 | 90.04K |
| Oct 9, 2026 | $11.99 | $12.20 | $11.95 | $12.03 | 44.85K |
| Oct 8, 2026 | $11.91 | $12.08 | $11.85 | $11.99 | 61.58K |
| Oct 7, 2026 | $12.00 | $12.05 | $11.86 | $12.02 | 74.94K |
| Oct 6, 2026 | $12.09 | $12.28 | $11.8254 | $12.07 | 75.42K |
| Oct 5, 2026 | $12.29 | $12.335 | $12.00 | $12.09 | 79.84K |
Latest AMRN news
The latest Smart Investors Daily articles mentioning AMRN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AMRN research
Overview
Company profile and research snapshot.
Company profile
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Underweight | — |
| Jun 25, 2025 | Goldman Sachs | Sell | — |
| Apr 17, 2025 | Goldman Sachs | Sell | — |
| Jun 20, 2024 | Cantor Fitzgerald | Overweight | — |
| Jun 18, 2024 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Amarin: Q3 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Amarin Corp. PLC (AMRN) on Wednesday reported third-quarter net income of $245,000, after reporting a loss in the same period a year earlier.
Yahoo · Oct 28, 2026
Amarin (AMRN) Q3 2026 Earnings Call Transcript
European demand surges 68% as Amarin returns to profitability.
Yahoo · Oct 28, 2026
Amarin Returns to Quarterly Profit as Cost Reductions Offset 20% Revenue Decline
Amarin Corporation plc (NASDAQ:AMRN) reported a net profit of $0. 2 million for the third quarter of 2026, marking its first profitable quarter in more than two years, as lower operating expenses helped offset declining revenue and continued pricing pressure in the United States.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
